Published in Hepatitis Weekly, January 30th, 2006
"Progression of hepatitis B in patients with lamivudine-resistant strains is slowed down by ADV. Whether the time point of ADV administration (genotypic vs. phenotypic resistance) influences the outcome of therapy is unknown."
"We compared the outcome of ADV therapy in hepatitis Be antigen (HBeAg)-negative chronic hepatitis B patients with genotypic and phenotypic resistance to lamivudine," wrote P. Lampertico and colleagues, University of Milan.
"Ten milligrams of ADV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.